STRATA Skin Sciences, Inc. (SSKN) 10-Year Financial Performance & Capital Metrics

SSKN • • Industrial / General

HealthcareMedical DevicesAesthetic & Reconstructive DevicesBreast Implants & Aesthetic Devices

AboutSTRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. Its products include XTRAC and Pharos excimer lasers, VTRAC lamp systems, and TheraClear treatment systems that are used for the treatment of psoriasis, vitiligo, acne, and other skin conditions. The company distributes its products internationally through distributors, and domestically directly to physicians. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.Show more

Revenue $34M +0.6%
EBITDA -$4M -46.1%
Net Income -$10M +6.9%
EPS (Diluted) -0.26 +16.1%
Gross Margin 56.85% +2.7%
EBITDA Margin -11.76% -45.2%
Operating Margin -27.58% -6.9%
Net Margin -30.05% +7.4%
ROE -114.22% -82.0%
ROIC -38.9% -39.8%
Debt/Equity 3.31 +168.3%
Interest Coverage -4.39 +16.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗High debt to equity ratio of 3.3x
✗Negative free cash flow
✗Weak momentum: RS Rating 9 (bottom 9%)
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y43.36%

5Y1.22%

3Y3.84%

TTM-5.19%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-17.66%

EPS CAGR

10Y-

5Y-

3Y-

TTM-335.46%

ROCE

10Y Avg-18.97%

5Y Avg-20.45%

3Y Avg-24.63%

Latest-36.03%

Peer Comparison

Breast Implants & Aesthetic Devices

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INMDInMode Ltd.	888.09M	14.05	6.24	-19.76%	41.04%	22.89%	14.86%	0.01
RCELAVITA Medical, Inc.	105.51M	3.46	-1.45	28.14%	-68.87%	-230.96%		10.22
SSKNSTRATA Skin Sciences, Inc.	7.6M	1.29	-4.96	0.61%	-35.64%	-8.4%		3.31
ESTAEstablishment Labs Holdings Inc.	1.92B	65.96	-21.99	0.53%	-43.45%	-5.07%		4.24

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	18.5M	31.76M	31.45M	29.86M	31.59M	23.09M	29.98M	36.16M	33.36M	33.56M
Revenue Growth %	19.21%	0.72%	-0.01%	-0.05%	0.06%	-0.27%	0.3%	0.21%	-0.08%	0.01%
Cost of Goods Sold+	13.72M	12.64M	13.5M	12.73M	11.32M	8.96M	10.13M	14.39M	14.9M	14.48M
COGS % of Revenue	0.74%	0.4%	0.43%	0.43%	0.36%	0.39%	0.34%	0.4%	0.45%	0.43%
Gross Profit+	4.78M	19.12M	17.95M	17.12M	20.27M	14.13M	19.85M	21.77M	18.46M	19.08M
Gross Margin %	0.26%	0.6%	0.57%	0.57%	0.64%	0.61%	0.66%	0.6%	0.55%	0.57%
Gross Profit Growth %	2.19%	3%	-0.06%	-0.05%	0.18%	-0.3%	0.4%	0.1%	-0.15%	0.03%
Operating Expenses+	21.25M	22.72M	20.36M	20.48M	23.28M	18.21M	24.25M	26.42M	27.07M	28.34M
OpEx % of Revenue	1.15%	0.72%	0.65%	0.69%	0.74%	0.79%	0.81%	0.73%	0.81%	0.84%
Selling, General & Admin	19.22M	20.79M	18.65M	19.41M	22.28M	16.94M	22.82M	25.39M	23.46M	23.59M
SG&A % of Revenue	1.04%	0.65%	0.59%	0.65%	0.71%	0.73%	0.76%	0.7%	0.7%	0.7%
Research & Development	2.03M	1.93M	1.71M	1.06M	1M	1.27M	1.43M	1.03M	1.32M	883K
R&D % of Revenue	0.11%	0.06%	0.05%	0.04%	0.03%	0.06%	0.05%	0.03%	0.04%	0.03%
Other Operating Expenses	33K	21K	17K	200K	0	0	0	0	2.28M	3.86M
Operating Income+	-16.48M	-3.6M	-2.41M	-3.35M	-3.01M	-4.08M	-4.4M	-4.65M	-8.6M	-9.26M
Operating Margin %	-0.89%	-0.11%	-0.08%	-0.11%	-0.1%	-0.18%	-0.15%	-0.13%	-0.26%	-0.28%
Operating Income Growth %	0.01%	0.78%	0.33%	-0.39%	0.1%	-0.35%	-0.08%	-0.06%	-0.85%	-0.08%
EBITDA+	-12.42M	2.77M	3.93M	2.04M	1.81M	-165K	-316K	1.04M	-2.7M	-3.95M
EBITDA Margin %	-0.67%	0.09%	0.12%	0.07%	0.06%	-0.01%	-0.01%	0.03%	-0.08%	-0.12%
EBITDA Growth %	0.16%	1.22%	0.42%	-0.48%	-0.11%	-1.09%	-0.92%	4.29%	-3.6%	-0.46%
D&A (Non-Cash Add-back)	4.05M	6.37M	6.34M	5.4M	4.82M	3.91M	4.09M	5.69M	5.9M	5.31M
EBIT	-16.48M	-3.6M	-1.8M	-3.35M	-3.01M	-3.93M	-2.36M	-4.56M	-9.28M	-8.15M
Net Interest Income+	-10.2M	-4.9M	-3.2M	-1.14M	-515K	-61K	-299K	-837K	-1.41M	-1.86M
Interest Income	0	0	0	0	0	150K	15K	89K	231K	242K
Interest Expense	10.2M	4.9M	3.2M	1.14M	515K	211K	314K	926K	1.64M	2.11M
Other Income/Expense	-8.35M	517K	-19.59M	-942K	-929K	-61K	1.73M	-837K	-2.32M	-1M
Pretax Income+	-24.83M	-3.08M	-18.7M	-4.3M	-3.94M	-4.14M	-2.67M	-5.49M	-10.92M	-10.26M
Pretax Margin %	-1.34%	-0.1%	-0.59%	-0.14%	-0.12%	-0.18%	-0.09%	-0.15%	-0.33%	-0.31%
Income Tax+	119K	255K	129K	-264K	-149K	275K	34K	63K	-92K	-170K
Effective Tax Rate %	1.12%	1.08%	1.15%	0.94%	0.96%	1.07%	1.01%	1.01%	0.99%	0.98%
Net Income+	-27.91M	-3.33M	-21.51M	-4.03M	-3.79M	-4.41M	-2.71M	-5.55M	-10.83M	-10.09M
Net Margin %	-1.51%	-0.11%	-0.68%	-0.14%	-0.12%	-0.19%	-0.09%	-0.15%	-0.32%	-0.3%
Net Income Growth %	-0.74%	0.88%	-5.45%	0.81%	0.06%	-0.16%	0.39%	-1.05%	-0.95%	0.07%
Net Income (Continuing)	-24.95M	-3.33M	-21.51M	-4.03M	-3.79M	-4.41M	-2.71M	-5.55M	-10.83M	-10.09M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-163.46	-1.44	-3.26	-0.15	-0.12	-0.13	-0.08	-0.16	-0.31	-0.26
EPS Growth %	-3.99%	0.99%	-1.26%	0.95%	0.2%	-0.08%	0.39%	-1.01%	-0.94%	0.16%
EPS (Basic)	-163.50	-3.77	-3.26	-0.15	-0.12	-0.13	-0.08	-0.16	-0.31	-0.26
Diluted Shares Outstanding	170.73K	2.32M	6.6M	27.17M	31.98M	33.61M	34.05M	34.71M	34.92M	38.07M
Basic Shares Outstanding	170.7K	884.61K	6.6M	27.17M	31.98M	33.61M	34.05M	34.71M	34.92M	38.07M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	11.98M	10.75M	10.75M	23.21M	23.55M	24.83M	19.97M	17.5M	15.54M	16.59M
Cash & Short-Term Investments	3.3M	3.93M	4.07M	16.49M	8.13M	10.6M	12.59M	5.43M	6.78M	7.26M
Cash Only	3.3M	3.93M	4.07M	16.49M	8.13M	10.6M	12.59M	5.43M	6.78M	7.26M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	4.07M	3.39M	3.14M	3.39M	4.39M	2.94M	3.43M	4.47M	4.44M	5.25M
Days Sales Outstanding	80.28	38.96	36.45	41.48	50.68	46.54	41.8	45.13	48.58	57.13
Inventory	4.13M	2.82M	3.01M	2.79M	3.03M	3.44M	3.49M	5.55M	2.67M	2.25M
Days Inventory Outstanding	109.83	81.37	81.37	80.08	97.64	140.36	125.75	140.67	65.49	56.61
Other Current Assets	15K	617K	533K	0	7.5M	7.51M	0	2.05M	1.65M	1.83M
Total Non-Current Assets+	39.39M	32.44M	27.88M	24.3M	23.79M	21.95M	26.62M	34.77M	26.47M	19.56M
Property, Plant & Equipment	13.85M	10.18M	7.7M	5.3M	6.68M	6.52M	7.52M	8.47M	12.4M	11.32M
Fixed Asset Turnover	1.34x	3.12x	4.08x	5.63x	4.73x	3.54x	3.99x	4.27x	2.69x	2.96x
Goodwill	8.93M	8.8M	8.8M	8.8M	8.8M	8.8M	8.8M	8.8M	6.52M	2.66M
Intangible Assets	15.23M	13.41M	11.32M	9.77M	7.96M	6.34M	10.08M	17.39M	7.32M	5.35M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	1.39M	46K	48K	428K	347K	282K	216K	98K	231K	231K
Total Assets+	51.37M	43.19M	38.63M	47.51M	47.34M	46.78M	46.59M	52.27M	42.02M	36.16M
Asset Turnover	0.36x	0.74x	0.81x	0.63x	0.67x	0.49x	0.64x	0.69x	0.79x	0.93x
Asset Growth %	1.56%	-0.16%	-0.11%	0.23%	-0%	-0.01%	-0%	0.12%	-0.2%	-0.14%
Total Current Liabilities+	6.78M	6.13M	7.67M	8.62M	17.43M	18.84M	12.8M	13.43M	12.17M	14.63M
Accounts Payable	4.45M	1.85M	2.28M	1.76M	1.88M	2.76M	2.82M	3.42M	3.34M	2.43M
Days Payables Outstanding	118.29	53.53	61.57	50.56	60.64	112.65	101.71	86.86	81.91	61.32
Short-Term Debt	299K	2.05M	2.74M	252K	7.28M	8.75M	0	0	0	0
Deferred Revenue (Current)	173K	235K	291K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	825K	376K	2.06M	506K	748K	891K	2.05M	4.87M	1.73M	2.81M
Current Ratio	1.77x	1.75x	1.40x	2.69x	1.35x	1.32x	1.56x	1.30x	1.28x	1.13x
Quick Ratio	1.16x	1.29x	1.01x	2.37x	1.18x	1.14x	1.29x	0.89x	1.06x	0.98x
Cash Conversion Cycle	71.82	66.81	56.25	71	87.68	74.25	65.84	98.94	32.17	52.41
Total Non-Current Liabilities+	28.5M	22.34M	8.71M	7.64M	1.26M	2.05M	8.38M	17.02M	17.15M	16.56M
Long-Term Debt	19.69M	21.78M	7.85M	7.14M	0	1.05M	7.32M	7.48M	15.04M	15.19M
Capital Lease Obligations	0	0	0	0	1.08M	710K	392K	610K	237K	919K
Deferred Tax Liabilities	119K	359K	414K	111K	-115K	254K	266K	306K	186K	0
Other Non-Current Liabilities	7.1M	202K	511K	388K	178K	34K	0	8.31M	1.69M	449K
Total Liabilities	35.28M	28.47M	16.39M	16.26M	18.69M	20.89M	21.18M	30.44M	29.33M	31.18M
Total Debt+	21.28M	23.83M	10.6M	7.4M	8.67M	10.88M	8.03M	8.44M	15.63M	16.44M
Net Debt	17.98M	19.91M	6.53M	-9.09M	537K	278K	-4.56M	3.01M	8.85M	9.18M
Debt / Equity	1.32x	1.62x	0.48x	0.24x	0.30x	0.42x	0.32x	0.39x	1.23x	3.31x
Debt / EBITDA	-	8.61x	2.70x	3.62x	4.79x	-	-	8.12x	-	-
Net Debt / EBITDA	-	7.19x	1.66x	-4.45x	0.30x	-	-	2.89x	-	-
Interest Coverage	-1.62x	-0.73x	-0.75x	-2.94x	-5.84x	-19.32x	-14.02x	-5.02x	-5.25x	-4.39x
Total Equity+	16.09M	14.72M	22.25M	31.25M	28.65M	25.89M	25.41M	21.83M	12.69M	4.97M
Equity Growth %	0.31%	-0.09%	0.51%	0.4%	-0.08%	-0.1%	-0.02%	-0.14%	-0.42%	-0.61%
Book Value per Share	94.22	6.36	3.37	1.15	0.90	0.77	0.75	0.63	0.36	0.13
Total Shareholders' Equity	16.09M	14.72M	22.25M	31.25M	28.65M	25.89M	25.41M	21.83M	12.69M	4.97M
Common Stock	10K	11K	4K	30K	33K	34K	34K	35K	4K	4K
Retained Earnings	-207.24M	-210.57M	-229.41M	-210.77M	-214.56M	-218.97M	-221.68M	-227.23M	-238.06M	-248.14M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	1K	2K	-10.73M	-13.53M	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-6.58M	322K	4.14M	2.9M	2.23M	2.1M	1.51M	-1.11M	-519K	188K
Operating CF Margin %	-0.36%	0.01%	0.13%	0.1%	0.07%	0.09%	0.05%	-0.03%	-0.02%	0.01%
Operating CF Growth %	0.63%	1.05%	11.86%	-0.3%	-0.23%	-0.06%	-0.28%	-1.73%	0.53%	1.36%
Net Income	-24.95M	-3.33M	-18.83M	-4.03M	-3.79M	-4.41M	-2.71M	-5.55M	-10.83M	-10.09M
Depreciation & Amortization	4.05M	6.37M	6.34M	5.4M	4.82M	3.91M	4.09M	5.69M	5.9M	5.31M
Stock-Based Compensation	1.75M	113K	186K	904K	1.2M	1.63M	1.64M	1.47M	1.3M	427K
Deferred Taxes	119K	240K	55K	-303K	-111K	254K	12K	40K	-120K	-186K
Other Non-Cash Items	12.81M	-2.48M	15.03M	717K	247K	114K	-1.85M	316K	3.29M	4.04M
Working Capital Changes	-375K	-583K	1.36M	214K	-133K	596K	324K	-3.07M	-69K	688K
Change in Receivables	-186K	558K	184K	-222K	-1.04M	1.35M	-490K	-1.15M	141K	-631K
Change in Inventory	-508K	1.31M	-193K	215K	-233K	-417K	-45K	-1.52M	689K	572K
Change in Payables	542K	-2.6M	381K	-513K	116K	884K	58K	603K	-100K	-954K
Cash from Investing+	-44.22M	-868K	-2.19M	-1.78M	-2.79M	-2.16M	-7.13M	-4.18M	-5.02M	-1.64M
Capital Expenditures	-1.69M	-1.01M	-1.74M	-1.76M	-2.79M	-2.16M	-3.65M	-3.55M	-5.02M	-1.64M
CapEx % of Revenue	0.09%	0.03%	0.06%	0.06%	0.09%	0.09%	0.12%	0.1%	0.15%	0.05%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-35K	15K	-455K	-23K	0	0	0	0	0	0
Cash from Financing+	42.67M	1.17M	-1.8M	11.31M	-296K	2.55M	92K	-500K	6.86M	1.93M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-134K	0	0	-2.34M	0	0	-133K	-500K	-139K	-18K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-8.27M	-686K	2.4M	1.13M	-562K	-63K	-2.15M	-4.66M	-5.54M	-1.45M
FCF Margin %	-0.45%	-0.02%	0.08%	0.04%	-0.02%	-0%	-0.07%	-0.13%	-0.17%	-0.04%
FCF Growth %	0.53%	0.92%	4.5%	-0.53%	-1.5%	0.89%	-33.05%	-1.17%	-0.19%	0.74%
FCF per Share	-48.46	-0.30	0.36	0.04	-0.02	-0.00	-0.06	-0.13	-0.16	-0.04
FCF Conversion (FCF/Net Income)	0.24x	-0.10x	-0.19x	-0.72x	-0.59x	-0.48x	-0.56x	0.20x	0.05x	-0.02x
Interest Paid	0	0	2.21M	1.01M	766K	0	0	744K	1.42M	1.97M
Taxes Paid	0	0	28K	17K	0	0	0	19K	22K	23K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-196.8%	-21.65%	-116.41%	-15.08%	-12.65%	-16.18%	-10.55%	-23.49%	-62.75%	-114.22%
Return on Invested Capital (ROIC)	-61.92%	-7.85%	-5.7%	-9.88%	-8.79%	-11.04%	-14.04%	-15.26%	-27.83%	-38.9%
Gross Margin	25.82%	60.21%	57.08%	57.34%	64.17%	61.21%	66.22%	60.2%	55.34%	56.85%
Net Margin	-150.9%	-10.5%	-68.41%	-13.51%	-12%	-19.11%	-9.03%	-15.35%	-32.47%	-30.05%
Debt / Equity	1.32x	1.62x	0.48x	0.24x	0.30x	0.42x	0.32x	0.39x	1.23x	3.31x
Interest Coverage	-1.62x	-0.73x	-0.75x	-2.94x	-5.84x	-19.32x	-14.02x	-5.02x	-5.25x	-4.39x
FCF Conversion	0.24x	-0.10x	-0.19x	-0.72x	-0.59x	-0.48x	-0.56x	0.20x	0.05x	-0.02x
Revenue Growth	1921.31%	71.71%	-0.97%	-5.07%	5.8%	-26.9%	29.83%	20.63%	-7.75%	0.61%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Dermatology Recurring Procedures	14.62M	24.56M	22.64M	21.05M	23.64M	561K	22.53M	23.02M	21.53M	21.17M
Dermatology Recurring Procedures Growth	-	68.02%	-7.81%	-7.01%	12.31%	-97.63%	3915.69%	2.21%	-6.49%	-1.67%
Dermatology Procedures Equipment	3.59M	7.07M	8.79M	8.8M	6.63M	4.72M	7.45M	13.14M	11.83M	12.39M
Dermatology Procedures Equipment Growth	-	96.74%	24.44%	0.11%	-24.68%	-28.73%	57.65%	76.35%	-9.96%	4.76%
Dermatology Imaging	288K	134K	17K	-	-	-	-	-	-	-
Dermatology Imaging Growth	-	-53.47%	-87.31%	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	-	-	-	-	-	-	-	-	-	20.89M
UNITED STATES Growth	-	-	-	-	-	-	-	-	-	-
China	-	-	-	-	-	-	-	4.75M	3.34M	4.07M
China Growth	-	-	-	-	-	-	-	-	-29.70%	21.83%
Domestic	14.72M	25.54M	26.18M	-	-	-	23.2M	23.98M	23.03M	-
Domestic Growth	-	73.43%	2.51%	-	-	-	-	3.38%	-3.97%	-
Korea	-	-	-	-	-	-	-	3.72M	2.73M	-
Korea Growth	-	-	-	-	-	-	-	-	-26.59%	-
Foreign	3.77M	6.22M	5.27M	-	-	-	6.78M	-	-	-
Foreign Growth	-	64.97%	-15.27%	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

STRATA Skin Sciences, Inc. (SSKN) reported $31.0M in revenue for fiscal year 2024.

STRATA Skin Sciences, Inc. (SSKN) grew revenue by 0.6% over the past year. Growth has been modest.

STRATA Skin Sciences, Inc. (SSKN) reported a net loss of $11.0M for fiscal year 2024.

Dividend & Returns

STRATA Skin Sciences, Inc. (SSKN) has a return on equity (ROE) of -114.2%. Negative ROE indicates the company is unprofitable.

STRATA Skin Sciences, Inc. (SSKN) had negative free cash flow of $3.5M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

STRATA Skin Sciences, Inc. (SSKN) 10-Year Financial Performance & Capital Metrics

SSKN • • Industrial / General

HealthcareMedical DevicesAesthetic & Reconstructive DevicesBreast Implants & Aesthetic Devices

Revenue $34M +0.6%
EBITDA -$4M -46.1%
Net Income -$10M +6.9%
EPS (Diluted) -0.26 +16.1%
Gross Margin 56.85% +2.7%
EBITDA Margin -11.76% -45.2%
Operating Margin -27.58% -6.9%
Net Margin -30.05% +7.4%
ROE -114.22% -82.0%
ROIC -38.9% -39.8%
Debt/Equity 3.31 +168.3%
Interest Coverage -4.39 +16.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗High debt to equity ratio of 3.3x
✗Negative free cash flow
✗Weak momentum: RS Rating 9 (bottom 9%)
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y43.36%

5Y1.22%

3Y3.84%

TTM-5.19%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-17.66%

EPS CAGR

10Y-

5Y-

3Y-

TTM-335.46%

ROCE

10Y Avg-18.97%

5Y Avg-20.45%

3Y Avg-24.63%

Latest-36.03%

Peer Comparison

Breast Implants & Aesthetic Devices

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INMDInMode Ltd.	888.09M	14.05	6.24	-19.76%	41.04%	22.89%	14.86%	0.01
RCELAVITA Medical, Inc.	105.51M	3.46	-1.45	28.14%	-68.87%	-230.96%		10.22
SSKNSTRATA Skin Sciences, Inc.	7.6M	1.29	-4.96	0.61%	-35.64%	-8.4%		3.31
ESTAEstablishment Labs Holdings Inc.	1.92B	65.96	-21.99	0.53%	-43.45%	-5.07%		4.24

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	18.5M	31.76M	31.45M	29.86M	31.59M	23.09M	29.98M	36.16M	33.36M	33.56M
Revenue Growth %	19.21%	0.72%	-0.01%	-0.05%	0.06%	-0.27%	0.3%	0.21%	-0.08%	0.01%
Cost of Goods Sold+	13.72M	12.64M	13.5M	12.73M	11.32M	8.96M	10.13M	14.39M	14.9M	14.48M
COGS % of Revenue	0.74%	0.4%	0.43%	0.43%	0.36%	0.39%	0.34%	0.4%	0.45%	0.43%
Gross Profit+	4.78M	19.12M	17.95M	17.12M	20.27M	14.13M	19.85M	21.77M	18.46M	19.08M
Gross Margin %	0.26%	0.6%	0.57%	0.57%	0.64%	0.61%	0.66%	0.6%	0.55%	0.57%
Gross Profit Growth %	2.19%	3%	-0.06%	-0.05%	0.18%	-0.3%	0.4%	0.1%	-0.15%	0.03%
Operating Expenses+	21.25M	22.72M	20.36M	20.48M	23.28M	18.21M	24.25M	26.42M	27.07M	28.34M
OpEx % of Revenue	1.15%	0.72%	0.65%	0.69%	0.74%	0.79%	0.81%	0.73%	0.81%	0.84%
Selling, General & Admin	19.22M	20.79M	18.65M	19.41M	22.28M	16.94M	22.82M	25.39M	23.46M	23.59M
SG&A % of Revenue	1.04%	0.65%	0.59%	0.65%	0.71%	0.73%	0.76%	0.7%	0.7%	0.7%
Research & Development	2.03M	1.93M	1.71M	1.06M	1M	1.27M	1.43M	1.03M	1.32M	883K
R&D % of Revenue	0.11%	0.06%	0.05%	0.04%	0.03%	0.06%	0.05%	0.03%	0.04%	0.03%
Other Operating Expenses	33K	21K	17K	200K	0	0	0	0	2.28M	3.86M
Operating Income+	-16.48M	-3.6M	-2.41M	-3.35M	-3.01M	-4.08M	-4.4M	-4.65M	-8.6M	-9.26M
Operating Margin %	-0.89%	-0.11%	-0.08%	-0.11%	-0.1%	-0.18%	-0.15%	-0.13%	-0.26%	-0.28%
Operating Income Growth %	0.01%	0.78%	0.33%	-0.39%	0.1%	-0.35%	-0.08%	-0.06%	-0.85%	-0.08%
EBITDA+	-12.42M	2.77M	3.93M	2.04M	1.81M	-165K	-316K	1.04M	-2.7M	-3.95M
EBITDA Margin %	-0.67%	0.09%	0.12%	0.07%	0.06%	-0.01%	-0.01%	0.03%	-0.08%	-0.12%
EBITDA Growth %	0.16%	1.22%	0.42%	-0.48%	-0.11%	-1.09%	-0.92%	4.29%	-3.6%	-0.46%
D&A (Non-Cash Add-back)	4.05M	6.37M	6.34M	5.4M	4.82M	3.91M	4.09M	5.69M	5.9M	5.31M
EBIT	-16.48M	-3.6M	-1.8M	-3.35M	-3.01M	-3.93M	-2.36M	-4.56M	-9.28M	-8.15M
Net Interest Income+	-10.2M	-4.9M	-3.2M	-1.14M	-515K	-61K	-299K	-837K	-1.41M	-1.86M
Interest Income	0	0	0	0	0	150K	15K	89K	231K	242K
Interest Expense	10.2M	4.9M	3.2M	1.14M	515K	211K	314K	926K	1.64M	2.11M
Other Income/Expense	-8.35M	517K	-19.59M	-942K	-929K	-61K	1.73M	-837K	-2.32M	-1M
Pretax Income+	-24.83M	-3.08M	-18.7M	-4.3M	-3.94M	-4.14M	-2.67M	-5.49M	-10.92M	-10.26M
Pretax Margin %	-1.34%	-0.1%	-0.59%	-0.14%	-0.12%	-0.18%	-0.09%	-0.15%	-0.33%	-0.31%
Income Tax+	119K	255K	129K	-264K	-149K	275K	34K	63K	-92K	-170K
Effective Tax Rate %	1.12%	1.08%	1.15%	0.94%	0.96%	1.07%	1.01%	1.01%	0.99%	0.98%
Net Income+	-27.91M	-3.33M	-21.51M	-4.03M	-3.79M	-4.41M	-2.71M	-5.55M	-10.83M	-10.09M
Net Margin %	-1.51%	-0.11%	-0.68%	-0.14%	-0.12%	-0.19%	-0.09%	-0.15%	-0.32%	-0.3%
Net Income Growth %	-0.74%	0.88%	-5.45%	0.81%	0.06%	-0.16%	0.39%	-1.05%	-0.95%	0.07%
Net Income (Continuing)	-24.95M	-3.33M	-21.51M	-4.03M	-3.79M	-4.41M	-2.71M	-5.55M	-10.83M	-10.09M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-163.46	-1.44	-3.26	-0.15	-0.12	-0.13	-0.08	-0.16	-0.31	-0.26
EPS Growth %	-3.99%	0.99%	-1.26%	0.95%	0.2%	-0.08%	0.39%	-1.01%	-0.94%	0.16%
EPS (Basic)	-163.50	-3.77	-3.26	-0.15	-0.12	-0.13	-0.08	-0.16	-0.31	-0.26
Diluted Shares Outstanding	170.73K	2.32M	6.6M	27.17M	31.98M	33.61M	34.05M	34.71M	34.92M	38.07M
Basic Shares Outstanding	170.7K	884.61K	6.6M	27.17M	31.98M	33.61M	34.05M	34.71M	34.92M	38.07M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	11.98M	10.75M	10.75M	23.21M	23.55M	24.83M	19.97M	17.5M	15.54M	16.59M
Cash & Short-Term Investments	3.3M	3.93M	4.07M	16.49M	8.13M	10.6M	12.59M	5.43M	6.78M	7.26M
Cash Only	3.3M	3.93M	4.07M	16.49M	8.13M	10.6M	12.59M	5.43M	6.78M	7.26M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	4.07M	3.39M	3.14M	3.39M	4.39M	2.94M	3.43M	4.47M	4.44M	5.25M
Days Sales Outstanding	80.28	38.96	36.45	41.48	50.68	46.54	41.8	45.13	48.58	57.13
Inventory	4.13M	2.82M	3.01M	2.79M	3.03M	3.44M	3.49M	5.55M	2.67M	2.25M
Days Inventory Outstanding	109.83	81.37	81.37	80.08	97.64	140.36	125.75	140.67	65.49	56.61
Other Current Assets	15K	617K	533K	0	7.5M	7.51M	0	2.05M	1.65M	1.83M
Total Non-Current Assets+	39.39M	32.44M	27.88M	24.3M	23.79M	21.95M	26.62M	34.77M	26.47M	19.56M
Property, Plant & Equipment	13.85M	10.18M	7.7M	5.3M	6.68M	6.52M	7.52M	8.47M	12.4M	11.32M
Fixed Asset Turnover	1.34x	3.12x	4.08x	5.63x	4.73x	3.54x	3.99x	4.27x	2.69x	2.96x
Goodwill	8.93M	8.8M	8.8M	8.8M	8.8M	8.8M	8.8M	8.8M	6.52M	2.66M
Intangible Assets	15.23M	13.41M	11.32M	9.77M	7.96M	6.34M	10.08M	17.39M	7.32M	5.35M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	1.39M	46K	48K	428K	347K	282K	216K	98K	231K	231K
Total Assets+	51.37M	43.19M	38.63M	47.51M	47.34M	46.78M	46.59M	52.27M	42.02M	36.16M
Asset Turnover	0.36x	0.74x	0.81x	0.63x	0.67x	0.49x	0.64x	0.69x	0.79x	0.93x
Asset Growth %	1.56%	-0.16%	-0.11%	0.23%	-0%	-0.01%	-0%	0.12%	-0.2%	-0.14%
Total Current Liabilities+	6.78M	6.13M	7.67M	8.62M	17.43M	18.84M	12.8M	13.43M	12.17M	14.63M
Accounts Payable	4.45M	1.85M	2.28M	1.76M	1.88M	2.76M	2.82M	3.42M	3.34M	2.43M
Days Payables Outstanding	118.29	53.53	61.57	50.56	60.64	112.65	101.71	86.86	81.91	61.32
Short-Term Debt	299K	2.05M	2.74M	252K	7.28M	8.75M	0	0	0	0
Deferred Revenue (Current)	173K	235K	291K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	825K	376K	2.06M	506K	748K	891K	2.05M	4.87M	1.73M	2.81M
Current Ratio	1.77x	1.75x	1.40x	2.69x	1.35x	1.32x	1.56x	1.30x	1.28x	1.13x
Quick Ratio	1.16x	1.29x	1.01x	2.37x	1.18x	1.14x	1.29x	0.89x	1.06x	0.98x
Cash Conversion Cycle	71.82	66.81	56.25	71	87.68	74.25	65.84	98.94	32.17	52.41
Total Non-Current Liabilities+	28.5M	22.34M	8.71M	7.64M	1.26M	2.05M	8.38M	17.02M	17.15M	16.56M
Long-Term Debt	19.69M	21.78M	7.85M	7.14M	0	1.05M	7.32M	7.48M	15.04M	15.19M
Capital Lease Obligations	0	0	0	0	1.08M	710K	392K	610K	237K	919K
Deferred Tax Liabilities	119K	359K	414K	111K	-115K	254K	266K	306K	186K	0
Other Non-Current Liabilities	7.1M	202K	511K	388K	178K	34K	0	8.31M	1.69M	449K
Total Liabilities	35.28M	28.47M	16.39M	16.26M	18.69M	20.89M	21.18M	30.44M	29.33M	31.18M
Total Debt+	21.28M	23.83M	10.6M	7.4M	8.67M	10.88M	8.03M	8.44M	15.63M	16.44M
Net Debt	17.98M	19.91M	6.53M	-9.09M	537K	278K	-4.56M	3.01M	8.85M	9.18M
Debt / Equity	1.32x	1.62x	0.48x	0.24x	0.30x	0.42x	0.32x	0.39x	1.23x	3.31x
Debt / EBITDA	-	8.61x	2.70x	3.62x	4.79x	-	-	8.12x	-	-
Net Debt / EBITDA	-	7.19x	1.66x	-4.45x	0.30x	-	-	2.89x	-	-
Interest Coverage	-1.62x	-0.73x	-0.75x	-2.94x	-5.84x	-19.32x	-14.02x	-5.02x	-5.25x	-4.39x
Total Equity+	16.09M	14.72M	22.25M	31.25M	28.65M	25.89M	25.41M	21.83M	12.69M	4.97M
Equity Growth %	0.31%	-0.09%	0.51%	0.4%	-0.08%	-0.1%	-0.02%	-0.14%	-0.42%	-0.61%
Book Value per Share	94.22	6.36	3.37	1.15	0.90	0.77	0.75	0.63	0.36	0.13
Total Shareholders' Equity	16.09M	14.72M	22.25M	31.25M	28.65M	25.89M	25.41M	21.83M	12.69M	4.97M
Common Stock	10K	11K	4K	30K	33K	34K	34K	35K	4K	4K
Retained Earnings	-207.24M	-210.57M	-229.41M	-210.77M	-214.56M	-218.97M	-221.68M	-227.23M	-238.06M	-248.14M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	1K	2K	-10.73M	-13.53M	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-6.58M	322K	4.14M	2.9M	2.23M	2.1M	1.51M	-1.11M	-519K	188K
Operating CF Margin %	-0.36%	0.01%	0.13%	0.1%	0.07%	0.09%	0.05%	-0.03%	-0.02%	0.01%
Operating CF Growth %	0.63%	1.05%	11.86%	-0.3%	-0.23%	-0.06%	-0.28%	-1.73%	0.53%	1.36%
Net Income	-24.95M	-3.33M	-18.83M	-4.03M	-3.79M	-4.41M	-2.71M	-5.55M	-10.83M	-10.09M
Depreciation & Amortization	4.05M	6.37M	6.34M	5.4M	4.82M	3.91M	4.09M	5.69M	5.9M	5.31M
Stock-Based Compensation	1.75M	113K	186K	904K	1.2M	1.63M	1.64M	1.47M	1.3M	427K
Deferred Taxes	119K	240K	55K	-303K	-111K	254K	12K	40K	-120K	-186K
Other Non-Cash Items	12.81M	-2.48M	15.03M	717K	247K	114K	-1.85M	316K	3.29M	4.04M
Working Capital Changes	-375K	-583K	1.36M	214K	-133K	596K	324K	-3.07M	-69K	688K
Change in Receivables	-186K	558K	184K	-222K	-1.04M	1.35M	-490K	-1.15M	141K	-631K
Change in Inventory	-508K	1.31M	-193K	215K	-233K	-417K	-45K	-1.52M	689K	572K
Change in Payables	542K	-2.6M	381K	-513K	116K	884K	58K	603K	-100K	-954K
Cash from Investing+	-44.22M	-868K	-2.19M	-1.78M	-2.79M	-2.16M	-7.13M	-4.18M	-5.02M	-1.64M
Capital Expenditures	-1.69M	-1.01M	-1.74M	-1.76M	-2.79M	-2.16M	-3.65M	-3.55M	-5.02M	-1.64M
CapEx % of Revenue	0.09%	0.03%	0.06%	0.06%	0.09%	0.09%	0.12%	0.1%	0.15%	0.05%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-35K	15K	-455K	-23K	0	0	0	0	0	0
Cash from Financing+	42.67M	1.17M	-1.8M	11.31M	-296K	2.55M	92K	-500K	6.86M	1.93M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-134K	0	0	-2.34M	0	0	-133K	-500K	-139K	-18K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-8.27M	-686K	2.4M	1.13M	-562K	-63K	-2.15M	-4.66M	-5.54M	-1.45M
FCF Margin %	-0.45%	-0.02%	0.08%	0.04%	-0.02%	-0%	-0.07%	-0.13%	-0.17%	-0.04%
FCF Growth %	0.53%	0.92%	4.5%	-0.53%	-1.5%	0.89%	-33.05%	-1.17%	-0.19%	0.74%
FCF per Share	-48.46	-0.30	0.36	0.04	-0.02	-0.00	-0.06	-0.13	-0.16	-0.04
FCF Conversion (FCF/Net Income)	0.24x	-0.10x	-0.19x	-0.72x	-0.59x	-0.48x	-0.56x	0.20x	0.05x	-0.02x
Interest Paid	0	0	2.21M	1.01M	766K	0	0	744K	1.42M	1.97M
Taxes Paid	0	0	28K	17K	0	0	0	19K	22K	23K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-196.8%	-21.65%	-116.41%	-15.08%	-12.65%	-16.18%	-10.55%	-23.49%	-62.75%	-114.22%
Return on Invested Capital (ROIC)	-61.92%	-7.85%	-5.7%	-9.88%	-8.79%	-11.04%	-14.04%	-15.26%	-27.83%	-38.9%
Gross Margin	25.82%	60.21%	57.08%	57.34%	64.17%	61.21%	66.22%	60.2%	55.34%	56.85%
Net Margin	-150.9%	-10.5%	-68.41%	-13.51%	-12%	-19.11%	-9.03%	-15.35%	-32.47%	-30.05%
Debt / Equity	1.32x	1.62x	0.48x	0.24x	0.30x	0.42x	0.32x	0.39x	1.23x	3.31x
Interest Coverage	-1.62x	-0.73x	-0.75x	-2.94x	-5.84x	-19.32x	-14.02x	-5.02x	-5.25x	-4.39x
FCF Conversion	0.24x	-0.10x	-0.19x	-0.72x	-0.59x	-0.48x	-0.56x	0.20x	0.05x	-0.02x
Revenue Growth	1921.31%	71.71%	-0.97%	-5.07%	5.8%	-26.9%	29.83%	20.63%	-7.75%	0.61%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Dermatology Recurring Procedures	14.62M	24.56M	22.64M	21.05M	23.64M	561K	22.53M	23.02M	21.53M	21.17M
Dermatology Recurring Procedures Growth	-	68.02%	-7.81%	-7.01%	12.31%	-97.63%	3915.69%	2.21%	-6.49%	-1.67%
Dermatology Procedures Equipment	3.59M	7.07M	8.79M	8.8M	6.63M	4.72M	7.45M	13.14M	11.83M	12.39M
Dermatology Procedures Equipment Growth	-	96.74%	24.44%	0.11%	-24.68%	-28.73%	57.65%	76.35%	-9.96%	4.76%
Dermatology Imaging	288K	134K	17K	-	-	-	-	-	-	-
Dermatology Imaging Growth	-	-53.47%	-87.31%	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	-	-	-	-	-	-	-	-	-	20.89M
UNITED STATES Growth	-	-	-	-	-	-	-	-	-	-
China	-	-	-	-	-	-	-	4.75M	3.34M	4.07M
China Growth	-	-	-	-	-	-	-	-	-29.70%	21.83%
Domestic	14.72M	25.54M	26.18M	-	-	-	23.2M	23.98M	23.03M	-
Domestic Growth	-	73.43%	2.51%	-	-	-	-	3.38%	-3.97%	-
Korea	-	-	-	-	-	-	-	3.72M	2.73M	-
Korea Growth	-	-	-	-	-	-	-	-	-26.59%	-
Foreign	3.77M	6.22M	5.27M	-	-	-	6.78M	-	-	-
Foreign Growth	-	64.97%	-15.27%	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

STRATA Skin Sciences, Inc. (SSKN) reported $31.0M in revenue for fiscal year 2024.

STRATA Skin Sciences, Inc. (SSKN) grew revenue by 0.6% over the past year. Growth has been modest.

STRATA Skin Sciences, Inc. (SSKN) reported a net loss of $11.0M for fiscal year 2024.

Dividend & Returns

STRATA Skin Sciences, Inc. (SSKN) has a return on equity (ROE) of -114.2%. Negative ROE indicates the company is unprofitable.

STRATA Skin Sciences, Inc. (SSKN) had negative free cash flow of $3.5M in fiscal year 2024, likely due to heavy capital investments.